Unknown

Dataset Information

0

Development and evaluation of nanoemulsifying preconcentrate of curcumin for colon delivery.


ABSTRACT: The present study aimed to develop and optimize a nanoemulsifying preconcentrate formulation of curcumin with good emulsification ability and optimal globule size, for controlled targeting in colon. Content of formulation variables, namely, X1 (Peceol), X2 (Cremophor-EL), and X3 (Transcutol HP), were optimized by Box-Behnken design of experiments for its impact on mean globule size (Y1), emulsification time (Y2), and time required for drug release (85%) in phosphate buffer (pH 7.2), t 85% (Y3). Transmission electron micrographs confirmed that there is no coalescence among globules, with size range concordant with the globule size analysis by dynamic light scattering technique (100?nm). 3D plots indicated that concentration of formulation ingredients significantly influences the formulation properties (globule size, emulsification time, and drug release). In vitro release profile (in phosphate buffer; pH 7.2) represents the fact that more than 50% of the drug was released within initial 15?min whereas in vivo release showed limited systemic absorption (C max 200?ng/mL) of curcumin. Stability study ensures the protection of drug in alkaline media which may further confirm the localised delivery of drug to colonic region. Study demonstrated that the nanoemulsifying preconcentrate can be a promising system for the colon specific delivery of curcumin to treat local pathologies.

SUBMITTER: Wadhwa J 

PROVIDER: S-EPMC4377495 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

altmetric image

Publications

Development and evaluation of nanoemulsifying preconcentrate of curcumin for colon delivery.

Wadhwa Jyoti J   Asthana Abhay A   Shilakari Gyati G   Chopra Arun Kumar AK   Singh Ranjit R  

TheScientificWorldJournal 20150311


The present study aimed to develop and optimize a nanoemulsifying preconcentrate formulation of curcumin with good emulsification ability and optimal globule size, for controlled targeting in colon. Content of formulation variables, namely, X1 (Peceol), X2 (Cremophor-EL), and X3 (Transcutol HP), were optimized by Box-Behnken design of experiments for its impact on mean globule size (Y1), emulsification time (Y2), and time required for drug release (85%) in phosphate buffer (pH 7.2), t 85% (Y3).  ...[more]

Similar Datasets

| S-EPMC7181043 | biostudies-literature
| S-EPMC10137603 | biostudies-literature
| S-EPMC4605912 | biostudies-literature
| S-EPMC9284007 | biostudies-literature
| S-EPMC8468394 | biostudies-literature
| S-EPMC10139733 | biostudies-literature
| S-EPMC10609253 | biostudies-literature
| S-EPMC4662402 | biostudies-literature
| S-EPMC7032203 | biostudies-literature
| S-EPMC7397308 | biostudies-literature